Left main stem (LMS) disease is associated with significant morbidity and mortality. Traditionally coronary artery bypass grafting (CABG) has been the gold standard for treatment of these lesions. However over the past decade, percutaneous coronary intervention (PCI) has assumed a more prominent role in the treatment of LMS disease. With the advent of newer drug-eluting stents (DES) with an improved risk factor profile, better intravascular imaging modalities and careful patient selection, the use of PCI in this cohort is expanding. We review the current data to support this and discuss the on-going trials that will hopefully shed more light into the management of this complex disease.
Rajiv Rampat - Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, UK
David Hildick-Smith - Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, UK